Evidence map›Paper›PMID 34667217›Full record

ArticleScientific reports2021

Upregulation of CD22 by Chidamide promotes CAR T cells functionality.

Xin Yang, Qiuxia Yu, Hao Xu, Jianfeng Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. B-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy.International journal of molecular sciences · 2023
    Review
  16. Review
  17. [Exploration of CAR-T cell combination therapy strategies in lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xin YangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, NO.1095 Jie Fang Avenue, Wuhan, 430030, Hubei, China.
Qiuxia YuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, NO.1095 Jie Fang Avenue, Wuhan, 430030, Hubei, China.
Hao XuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, NO.1095 Jie Fang Avenue, Wuhan, 430030, Hubei, China. zyxuhao@163.com.
Jianfeng ZhouDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, NO.1095 Jie Fang Avenue, Wuhan, 430030, Hubei, China.
Huazhong University of Science and Technology · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment failure or relapse due to tumor escape caused by reduction in target antigen expression has become a challenge in the field of CART therapy. Target antigen density is closely related to the effectiveness of CART therapy, and reduced or lost target antigen expression limits the efficacy of CART therapy and hinders the durability of CAR T cells. Epigenetic drugs can regulate histones for molecular modifications to regulate the transcriptional, translational and post-translational modification processes of target agents, and we demonstrated for the first time the role in regulating CD22 expression and its effect on the efficacy of CD22 CART. In this paper, we found that Chidamide promoted the expression of CD22 on the surface of B-cell tumor cells in vitro and in vivo, and enhanced the function of CD22 CART. As for mechanisms, we demonstrated that Chidamide did not affect CD22 mRNA transcription, but significantly increased the expression of total CD22 protein, indicating that Chidamide may upregulate cell surface CD22 expression by affecting the distribution of CD22 protein. In summary, our results suggest that Chidamide may enhance the efficacy of CD22 CART by inhibiting histone deacetylases to regulate post-transcriptional modifications that affect protein distribution to increase the expression of CD22 on the cell surface.

Indexed as

AminopyridinesBenzamidesB-LymphocytesCell Line, TumorGene ExpressionHistone Deacetylase InhibitorsHistonesHumansImmunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrimary Cell CultureReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2T-LymphocytesUp-RegulationAminopyridinesBenzamidesCD22 protein, humanHistone Deacetylase InhibitorsHistonesN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2

Identifiers

PMID34667217
PMCPMC8526578
OpenAlexW3186335489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.